Clinical anticachexia treatments

Nutrition in Clinical Practice

Volumn 21, Issue 2, 2006, Pages 168-174

  Tisdale, Michael J ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE PHOSPHATE; APPETITE STIMULANT; BETA HYDROXY BETA METHYLBUTYRATE; CANNABINOID; CORTICOSTEROID; CYPROHEPTADINE; GESTAGEN; GROWTH HORMONE; I KAPPA B KINASE; IBUPROFEN; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUCINE; MEGESTROL ACETATE; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEASOME; SEROTONIN ANTAGONIST; THALIDOMIDE; UBIQUITIN; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; CACHEXIA; DRUG MECHANISM; EVALUATION RESEARCH; GRIP STRENGTH; HUMAN; MUSCLE MASS; MUSCLE WEAKNESS; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; QUALITY OF LIFE; REVIEW; SKELETAL MUSCLE; WEIGHT REDUCTION; ENERGY METABOLISM; METABOLISM; PHYSIOLOGY;

ADIPOSE TISSUE; ADRENAL CORTEX HORMONES; CACHEXIA; EICOSAPENTAENOIC ACID; ENERGY METABOLISM; HUMANS; MUSCLE, SKELETAL; PROGESTINS; PROTEIN BIOSYNTHESIS; THALIDOMIDE;

EID: 33747041711     PISSN: 08845336     EISSN: None     Source Type: Journal    
DOI: 10.1177/0115426506021002168     Document Type: Review

References (62)

1. Vigino A, Bruera E, Jhangri GS, Newman SC, Fields AL, Suarez-Almazor ME. Clinical survival predictors in patients with advanced cancer. Arch Intern Med. 2000;160:861-868.
2. Anker SD, Sharma R. The syndrome of cardiac cachexia. Int J Cardiol. 2002;85:51-66.
3. Kotter DP, Tiemey AR, Culpepper-Morgan JA, Wang J, Pierson RN. Effect of home total parenteral nutrition on body composition in patients with acquired immunodeficiency syndrome. JPEN J Parenter Enteral Nutr. 1990;14:454-458.
4. Persson C, Glimelius B. The relevance of weight loss for survival and quality of life in patients with advanced gastrointestinal cancer treated with palliative chemotherapy. Anticancer Res. 2002;22:3661-3668.
5. Acharyya S, Ladner KJ, Nelsen LL, et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest. 2004;114:370-378.
6. Lecker SH, Solomon V, Mitch WE, Goldberg AL. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr. 1999;129(1S suppl):227S-237S.
7. Li Y-P, Reid MB. NF-κB mediates the protein loss induced by TNF-α in differentiated skeletal muscle myotubes. Am J Physiol. 2000;279:R1165-R1170.
8. Whitehouse AS, Tisdale MJ. Increased expression of the ubiquitin-proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-κB. Br J Cancer. 2003;89:1116-1122.
9. Wyke SM, Russell ST, Tisdale MJ. Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-κB activation. Br J Cancer. 2004;91:1742-1750.
10. Bodine SC, Latres E, Baumheuter S, et al. Identification of ubiquitin-ligases required for skeletal muscle atrophy. Science. 2001;294:1704-1708.
11. Hirai K, Hussey HJ, Barber MD, Price SA, Tisdale MJ. Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res. 1998;58:2359-2365.
12. Souza SC, Palmer HJ, Kang Y-H, et al. TNF-α induction of lipolysis is mediated through activation of the extracellular signal related kinase pathway in 3T3-L1 adipocytes. J Cell Biochem. 2003;89:1077-1086.
13. Bing C, Bao Y, Jenkins J, et al. Zinc-α 2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc Natl Acad Sci U S A. 2004;101:2500-2505.
14. 2-glycoprotein expression in adipose tissue in cancer cachexia. Br J Cancer. 2005;92:876-881.
15. Strang P. The effect of megestrol acetate on anorexia, weight loss and cachexia in cancer and AIDS patients [review]. Anticancer Res. 1997;17:657-662.
16. Loprinzi CL, Schaid DJ, Dose AM, Burnham NL, Jensen MD. Body composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol. 1993;11:152-154.
17. Lambert CP, Sullivan DH, Freeling SA, Lindquist DM, Evans WJ. Effect of testosterone replacement and/or resistance exercise on the composition of megestrol acetate stimulated weight gain in elderly men: a randomized controlled trial. J Clin Endocrinol Metab. 2002;87:2100-2106.
18. Simons JPHA, Schols AMWJ, Hoefnagels JMJ, Westerterp KR, ten Velde GPM, Wouters EFM. Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, non-hormone sensitive cancer. Cancer. 1998;82:553-560.
19. Downer S, Joel S, Allbright A, et al. A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia. Br J Cancer. 1993;67:1102-1105.
20. Maltoni M, Nanni O, Scarpi E, Rossi D, Serra P, Amadori D. High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials. Ann Oncol. 2001;12:289-300.
21. Mantovani G, Maccio A, Esu S, et al. Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Eur J Cancer. 1997;33:602-607.
22. Invi A. Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res. 1999;59:4493-4501.
23. Popiela T, Lucchi R, Giongo F. Methylprednisolone as palliative therapy for female terminal cancer patients. Eur J Cancer Clin Oncol. 1989;25:1823-1829.
24. Wang L, Luo G-J, Wang J-J, Hasselgren P-O. Dexamethasone stimulates proteasome- and calcium-dependent proteolysis in cultured L6 myotubes. Shock. 1998;10:298-306.
25. Tisdale MJ, Dhesi JK. Inhibition of weight loss by ω-3 fatty acids in an experimental cachexia model. Cancer Res. 1990;50:5022-5026.
26. Tisdale MJ, Beck SA. Inhibition of tumour-induced lipolysis in vitro and cachexia and tumour growth in vivo by eicosapentaenoic acid. Biochem Pharmacol. 1991;41:103-107.
27. Smith HJ, Greenberg NA, Tisdale MJ. Effect of eicosapentaenoic acid, protein and amino acids on protein synthesis and degradation in skeletal muscle of cachectic mice. Br J Cancer. 2004;91:408-412.
28. Whitehouse AS, Smith HJ, Drake JL, Tisdale MJ. Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid. Cancer Res. 2001;61:3604-3609.
29. 12 myoblasts: modulation by eicosapentaenoic acid. Cancer Res. 1999;59:5507-5513.
30. Wigmore SJ, Ross JA, Falconer JS, et al. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition. 1996;12(suppl):527-530.
31. Wigmore SJ, Barber MD, Ross JA, Tisdale MJ, Fearon KCH. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer. 2000;36:177-184.
32. Barber MD, Ross JA, Voss AC, Tisdale MJ, Fearon KCH. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer. 1999;81:80-86.
33. Fearon KCH, von Meyenfeldt MF, Moses AGW, et al. Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut. 2003;52:1479-1486.
34. Moses AWG, Slater C, Preston T, Barber MD, Fearon KCH. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense supplement enriched with n-3 fatty acids. Br J Cancer. 2004;90:996-1002.
35. Jatoi A, Rowland K, Loprinzi CL, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol. 2004;22:2469-2476.
36. Gogos CA, Ginopoulos P, Salsa B, Apostolidou E, Zoumbos NC, Kalfarentzos F. Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy. Cancer. 1998;82:395-402.
37. Burns CP, Halabi S, Clamon G, et al. Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia. Cancer. 2004;101:370-378.
38. Bruera E, Strasser F, Palmer JL, et al. Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol. 2003;21:129-134.
39. Tramontana JM, Utaipat U, Molloy A, et al. Thalidomide treatment reduces tumor necrosis factor alpha and enhances weight gain in patients with pulmonary tuberculosis. Mol Med. 1995;1:384-397
40. Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, Arroyo-Figueroa H, Pasquetti A, Calva JJ. Effects of thalidomide on HIV-associated wasting syndrome; a randomised double-blind, placebo-controlled trial. AfOS. 1996;10:1501-1507.
41. Haslett P, Hempstead M, Seidman C, et al. The metabolic and immunological effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses. 1997;13:1047-1054.
42. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumour necrosis factor by enhancing mRNA degradation. J Exp Med. 1993;177:1675-1680.
43. Goldberg RM, Loprinzi CL, Mailliard JA, et al. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol. 1995;13:2856-2859.
44. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity. J Biol Chem. 2001;276:22382-22387.
45. Khan ZH, Simpson EJ, Cole AT, et al. Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. Aliment Pharmacol Ther. 2003;17:677-682.
46. Smith HJ, Mukerji P, Tisdale MJ. Attenuation of proteasome-induced proteolysis in skeletal muscle by β-hydroxy-β-methylbutyrate in cancer-induced muscle loss. Cancer Res. 2005;65:277-283.
47. Smith HJ, Wyke SM, Tisdale MJ. Mechanism of the attenuation of proteolysis-inducing factor stimulated protein degradation in muscle by β-hydroxy-β-methylbutyrate. Cancer Res. 2004;64:8731-8735.
48. Clark RH, Feleke G, Din M, et al. Nutritional treatment for acquired immunodeficiency virus-associated wasting using β-hydroxy-β- methylbutyrate, glutamine, and arginine: a randomized, double-blind, placebo-controlled study. JPEN J Parenter Enteral Nutr. 2000;24:133-139.
49. Eubanks P, Barber A, D'Olimpio JT, Hourichane A, Abumrad NN. Reversal of cancer-related wasting using oral supplementation with a combination of β-hydroxy-β-methylbutyrate, arginine and glutamine. Am J Surg. 2002;183:471-479.
50. Lundholm K, Gelin J, Hyltander A, Lonnroth C, Sandstrom R, Svaniger G. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res. 1994;54:5602-5606.
51. Wigmore SJ, Falconer JS, Plester CE, et al. Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients. Br J Cancer. 1995;72:185-188.
52. McMillan DC, Wigmore SJ, Fearon KCH, O'Gorman P, Wright CE, McArdle CS. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients. Br J Cancer. 1999;79:495-500.
53. Hussey HJ, Tisdale MJ. Effect of the specific cycloxygenase-2-inhibitor meloxicam on tumour growth and cachexia in a murine model. Int J Cancer. 2000;87:95-100.
54. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD. Constitutive activation of IκB kinase α and NF-κB in prostate cancer cells is inhibited by ibuprofen. Oncogene. 1999;18:7389-7394.
55. Rapaport E, Fontaine J. Generation of extracellular ATP in blood and its mediated inhibition of host weight loss in tumor-bearing mice. Biochem Pharmacol. 1989;38:4261-4266.
56. Agteresch HJ, Dagnelie PC, van der Gaast A, Stijnen T, Wilson JHP. Randomized clinical trial of adenosine 5′-triphosphate in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2000;92:321-328.
57. Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting: a randomized, placebo-controlled trial. Ann Intern Med. 1996;125:873-882.
58. Wadleigh R, Spalding GM, Lumbersky B, et al. Dronabinol enhancement of appetite and cancer patients [abstract]. Proc Am Soc Oncol. 1990;9:331.
59. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol. 2002;20:567-573.
60. Cangiano C, Laviano A, Meguid MM, et al. Effects of administration of oral based branched-chain amino acids on anorexia and caloric intake in cancer patients. J Natl Cancer Inst. 1996;88:50-51.
61. Kardinal C, Loprinzi C, Shaw P, et al. A controlled trial of cyproheptadine in cancer patients with anorexia. Cancer. 1990;65:2657-2662.
62. Edelman MJ, Gandara DR, Meyers FJ, et al. Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome. Cancer. 1999;86:684-688.